Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247152413> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2247152413 endingPage "7578" @default.
- W2247152413 startingPage "7578" @default.
- W2247152413 abstract "7578 Background: Vascular endothelial growth factor (VEGF) is a key growth factor for MM. In pre-clinical models, anti-VEGF antibodies inhibit MM proliferation. Standard chemotherapy for MM, pemetrexed + cisplatin, yields a response rate of 41%, progression-free survival (PFS) of 5.7 months (mo) and median overall survival (OS) of 12.1 mo. We added the anti-VEGF antibody B to PC in an ongoing phase II multi-center study in MM pts. Methods: Eligible pts have unresectable, histologically-confirmed MM, no prior chemotherapy, and PS 0–1. Pts receive C 75 mg/m 2 , P 500 mg/m 2 and B 15 mg/kg Q21 days for 6 cycles, then B Q21 days until progression. CT scans are obtained Q 2 cycles. Primary endpoint: Progression-fere survival (PFS). Correlative studies include IHC for the VEGF/KDR complex and PCR for simian virus 40 (sv40) T antigen. Results: 43 pts enrolled at 4 centers from 3/06 to 12/08; currently, 34 are evaluable for PFS and 36 for toxicity. Pt characteristics: male 88%; median age 66 (range 24–81); histology: epithelial 62%, sarcomatoid 15%, biphasic 20%, unknown 3%; site of origin: pleural 85%, peritoneal 12%, tunica vaginalis 3%; PS 0 32%, PS 1 68%; thrombocytosis (>400) 32%. Cycles administered 229 (median 4, range 1–18). Grade 3/4 toxicity (%pts): neutropenia 8%; anemia 0%; thrombocytopenia 3%; thrombosis 11%; hypertension 8%; vomiting 8%; mucositis 6%; CVA 3%; proteinuria 0%; perforation 0%. Partial response: 41%, stable disease: 35%. Median PFS: 5.6 mo (95% CI: 4.1, 7.2). Median OS 11.5 mo (95% CI: 9.4, 24). Conclusions: These data suggest that the addition of B to PC does not improve PFS when compared with historical controls of PC in advanced MM pts. Correlative studies evaluating the VEGF/KDR complex and sv40 T antigen are pending. [Table: see text]" @default.
- W2247152413 created "2016-06-24" @default.
- W2247152413 creator A5006731860 @default.
- W2247152413 creator A5030693092 @default.
- W2247152413 creator A5060545585 @default.
- W2247152413 creator A5061071630 @default.
- W2247152413 creator A5078275347 @default.
- W2247152413 creator A5090156519 @default.
- W2247152413 creator A5091812069 @default.
- W2247152413 date "2009-05-20" @default.
- W2247152413 modified "2023-09-27" @default.
- W2247152413 title "A multicenter phase II study of pemetrexed (P), cisplatin (C), and bevacizumab (B) in patients (pts) with advanced malignant mesothelioma (MM)" @default.
- W2247152413 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.7578" @default.
- W2247152413 hasPublicationYear "2009" @default.
- W2247152413 type Work @default.
- W2247152413 sameAs 2247152413 @default.
- W2247152413 citedByCount "5" @default.
- W2247152413 countsByYear W22471524132012 @default.
- W2247152413 countsByYear W22471524132014 @default.
- W2247152413 countsByYear W22471524132016 @default.
- W2247152413 crossrefType "journal-article" @default.
- W2247152413 hasAuthorship W2247152413A5006731860 @default.
- W2247152413 hasAuthorship W2247152413A5030693092 @default.
- W2247152413 hasAuthorship W2247152413A5060545585 @default.
- W2247152413 hasAuthorship W2247152413A5061071630 @default.
- W2247152413 hasAuthorship W2247152413A5078275347 @default.
- W2247152413 hasAuthorship W2247152413A5090156519 @default.
- W2247152413 hasAuthorship W2247152413A5091812069 @default.
- W2247152413 hasConcept C126322002 @default.
- W2247152413 hasConcept C126894567 @default.
- W2247152413 hasConcept C141071460 @default.
- W2247152413 hasConcept C2776694085 @default.
- W2247152413 hasConcept C2777063308 @default.
- W2247152413 hasConcept C2777240266 @default.
- W2247152413 hasConcept C2777802072 @default.
- W2247152413 hasConcept C2778239845 @default.
- W2247152413 hasConcept C2778496288 @default.
- W2247152413 hasConcept C2780739268 @default.
- W2247152413 hasConcept C31760486 @default.
- W2247152413 hasConcept C71924100 @default.
- W2247152413 hasConcept C90924648 @default.
- W2247152413 hasConceptScore W2247152413C126322002 @default.
- W2247152413 hasConceptScore W2247152413C126894567 @default.
- W2247152413 hasConceptScore W2247152413C141071460 @default.
- W2247152413 hasConceptScore W2247152413C2776694085 @default.
- W2247152413 hasConceptScore W2247152413C2777063308 @default.
- W2247152413 hasConceptScore W2247152413C2777240266 @default.
- W2247152413 hasConceptScore W2247152413C2777802072 @default.
- W2247152413 hasConceptScore W2247152413C2778239845 @default.
- W2247152413 hasConceptScore W2247152413C2778496288 @default.
- W2247152413 hasConceptScore W2247152413C2780739268 @default.
- W2247152413 hasConceptScore W2247152413C31760486 @default.
- W2247152413 hasConceptScore W2247152413C71924100 @default.
- W2247152413 hasConceptScore W2247152413C90924648 @default.
- W2247152413 hasIssue "15_suppl" @default.
- W2247152413 hasLocation W22471524131 @default.
- W2247152413 hasOpenAccess W2247152413 @default.
- W2247152413 hasPrimaryLocation W22471524131 @default.
- W2247152413 hasRelatedWork W1980050012 @default.
- W2247152413 hasRelatedWork W1984603361 @default.
- W2247152413 hasRelatedWork W2097463411 @default.
- W2247152413 hasRelatedWork W2119452401 @default.
- W2247152413 hasRelatedWork W2166950437 @default.
- W2247152413 hasRelatedWork W2168489763 @default.
- W2247152413 hasRelatedWork W2503036974 @default.
- W2247152413 hasRelatedWork W2605177043 @default.
- W2247152413 hasRelatedWork W4302291056 @default.
- W2247152413 hasRelatedWork W2118693777 @default.
- W2247152413 hasVolume "27" @default.
- W2247152413 isParatext "false" @default.
- W2247152413 isRetracted "false" @default.
- W2247152413 magId "2247152413" @default.
- W2247152413 workType "article" @default.